Colorectal Cancer's Cognitive Conundrum: Unraveling the Role of Lidocaine in Endoscopic Submucosal Dissection
Colorectal cancer, a global health burden with rising incidence, often requires endoscopic submucosal dissection (ESD) for early lesion removal. But here's the catch: the procedure's complexity demands deep sedation, raising concerns about cognitive recovery. Propofol, the go-to sedative, can compromise cerebral perfusion, leaving patients vulnerable to cognitive impairment. And this is the part most people miss: studies reveal that up to 18.5% of patients experience cognitive issues post-discharge, with long-term effects largely unexplored.
Enter intravenous lidocaine, a potential game-changer. Known for reducing propofol consumption and injection pain, lidocaine's neuroprotective properties have sparked interest. A systematic review by Wang et al. hints at its ability to reduce postoperative cognitive dysfunction, but results across trials are inconsistent. The controversy lies in whether lidocaine's benefits translate to endoscopic procedures, where sedation profiles differ from general anesthesia.
Our randomized controlled trial aimed to bridge this knowledge gap. We hypothesized that lidocaine would enhance cognitive recovery post-ESD, measured by the Postoperative Quality of Recovery Scale (PostopQRS). The results? Lidocaine significantly improved cognitive recovery at day 3 (92.3% vs 80.3%) and day 7 (98.3% vs 90.6%), reduced propofol consumption by 25%, and minimized injection pain. However, the study's exclusion criteria, including patients with organ dysfunction, limit generalizability.
The debate rages on: can lidocaine's cognitive benefits be extrapolated to high-risk populations? We invite discussion on this critical question. Should lidocaine become a standard adjuvant in endoscopic sedation, or are further studies needed to optimize dosing and assess long-term effects? Share your thoughts in the comments, and let's unravel the cognitive conundrum together.
